USF-LVHN SELECT
Reduced immunogenicity of MYC amplified, metastatic prostate cancer.
Publication/Presentation Date
1-1-2026
Abstract
OBJECTIVES: Through a genomics-based approach analyzing gene expression levels and adaptive immune receptor recombinations, we sought to determine whether MYC amplification was associated with a worse outcome and reduced immunogenicity.
METHODS: MYC copy numbers and the presence of adaptive immune receptor (IR) recombination sequencing reads were quantified in genomics files representing prostate cancer samples.
RESULTS: Our results showed that increased MYC amplification was found in metastatic stages of prostate cancer. Furthermore, increased MYC amplification was not only associated with worse progression-free survival but also with reduced immunogenicity in metastatic tumors, as determined by the recovery of a reduced numbers of adaptive IR recombination sequencing reads from tumor RNAseq and tumor whole genome sequence files.
CONCLUSIONS: MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics files.
Volume
13
First Page
35
Last Page
43
ISSN
2331-4737
Published In/Presented At
Kahlon, S., Barker, V. R., Varkhedi, M., Wang, A. Y., Huda, T. I., & Blanck, G. (2026). Reduced immunogenicity of MYC amplified, metastatic prostate cancer. Oncoscience, 13, 35–43. https://doi.org/10.18632/oncoscience.644
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
41743583
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article